The complete molecular response of CML treatment is defined as undetectable BCR-ABL transcripts, and the long-term therapeutic target for CML treatment is to maintain molecular response but only cytogenetic response. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.